» Articles » PMID: 38345650

Disease-Associated Neurotoxic Astrocyte Markers in Alzheimer Disease Based on Integrative Single-Nucleus RNA Sequencing

Overview
Publisher Springer
Date 2024 Feb 12
PMID 38345650
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer disease (AD) is an irreversible neurodegenerative disease, and astrocytes play a key role in its onset and progression. The aim of this study is to analyze the characteristics of neurotoxic astrocytes and identify novel molecular targets for slowing down the progression of AD. Single-nucleus RNA sequencing (snRNA-seq) data were analyzed from various AD cohorts comprising about 210,654 cells from 53 brain tissue. By integrating snRNA-seq data with bulk RNA-seq data, crucial astrocyte types and genes associated with the prognosis of patients with AD were identified. The expression of neurotoxic astrocyte markers was validated using 5 × FAD and wild-type (WT) mouse models, combined with experiments such as western blot, quantitative real-time PCR (qRT-PCR), and immunofluorescence. A group of neurotoxic astrocytes closely related to AD pathology was identified, which were involved in inflammatory responses and pathways related to neuron survival. Combining snRNA and bulk tissue data, ZEP36L, AEBP1, WWTR1, PHYHD1, DST and RASL12 were identified as toxic astrocyte markers closely related to disease severity, significantly elevated in brain tissues of 5 × FAD mice and primary astrocytes treated with Aβ. Among them, WWTR1 was significantly increased in astrocytes of 5 × FAD mice, driving astrocyte inflammatory responses, and has been identified as an important marker of neurotoxic astrocytes. snRNA-seq analysis reveals the biological functions of neurotoxic astrocytes. Six genes related to AD pathology were identified and validated, among which WWTR1 may be a novel marker of neurotoxic astrocytes.

Citing Articles

Mechanisms of astrocyte aging in reactivity and disease.

Gildea H, Liddelow S Mol Neurodegener. 2025; 20(1):21.

PMID: 39979986 PMC: 11844071. DOI: 10.1186/s13024-025-00810-7.


Astrocytes phenomics as new druggable targets in healthy aging and Alzheimer's disease progression.

Lana D, Ugolini F, Iovino L, Attorre S, Giovannini M Front Cell Neurosci. 2025; 18():1512985.

PMID: 39835288 PMC: 11743640. DOI: 10.3389/fncel.2024.1512985.


Comparative Analysis of Human Brain RNA-seq Reveals the Combined Effects of Ferroptosis and Autophagy on Alzheimer's Disease in Multiple Brain Regions.

Ye K, Zhao X, Liu L, Ge F, Zheng F, Liu Z Mol Neurobiol. 2024; .

PMID: 39710824 DOI: 10.1007/s12035-024-04642-2.


The dopamine analogue CA140 alleviates AD pathology, neuroinflammation, and rescues synaptic/cognitive functions by modulating DRD1 signaling or directly binding to Abeta.

Chae S, Lee H, Lee H, Kim J, Jeong Y, Lin Y J Neuroinflammation. 2024; 21(1):200.

PMID: 39129007 PMC: 11317008. DOI: 10.1186/s12974-024-03180-x.

References
1.
Troyanskaya O, Cantor M, Sherlock G, Brown P, Hastie T, Tibshirani R . Missing value estimation methods for DNA microarrays. Bioinformatics. 2001; 17(6):520-5. DOI: 10.1093/bioinformatics/17.6.520. View

2.
Stine W, Jungbauer L, Yu C, LaDu M . Preparing synthetic Aβ in different aggregation states. Methods Mol Biol. 2010; 670:13-32. PMC: 3752843. DOI: 10.1007/978-1-60761-744-0_2. View

3.
Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chetelat G, Teunissen C . Alzheimer's disease. Lancet. 2021; 397(10284):1577-1590. PMC: 8354300. DOI: 10.1016/S0140-6736(20)32205-4. View

4.
Adams K, Gallo V . The diversity and disparity of the glial scar. Nat Neurosci. 2017; 21(1):9-15. PMC: 5937232. DOI: 10.1038/s41593-017-0033-9. View

5.
Sun D, Guan X, Moran A, Wu L, Qian D, Schedin P . Identifying phenotype-associated subpopulations by integrating bulk and single-cell sequencing data. Nat Biotechnol. 2021; 40(4):527-538. PMC: 9010342. DOI: 10.1038/s41587-021-01091-3. View